European drug regulators indicate that the heart surgery medication Trasylol should be allowed back on the market, after questions have been raised about a study that led to the recall…
Canadian health officials are allowing the recalled heart surgery drug Trasylol back on the market in the country, but stress that it should not be used for off-label purposes.
Bayer has reportedly reached an agreement to settle about 150 Trasylol lawsuits filed on behalf of individuals who allege that the heart surgery drug increased the risk of kidney failure,…
Three Trasylol kidney failure lawsuits were filed last month in Illinois state court on behalf of 55 plaintiffs, who accuse Bayer of failing to adequately warn that a recalled heart…
Nearly two years after sales were halted, lawsuits continue to be filed against Bayer over the heart surgery drug Trasylol, which has been linked to an increased risk of kidney…
Although the Court granted a joint motion to delay the discovery schedule for Trasylol lawsuits consolidated in an MDL in the U.S. District Court for the Southern District of Florida,…
A class action lawsuit has been filed in Canada against Bayer involving their heart bypass surgery injection Trasylol. The lawsuit was filed the day after a new study was released…
A new lawsuit has been filed on behalf of two heart surgery patients who received an injection known as Trasylol before their operations to control bleeding. The suit seeks damages…
A heart surgery injection known as Trasylol, which is given to control bleeding during heart bypass surgery, has been associated with a significantly increased risk of kidney failure, heart attacks,…
After initially issuing a temporary withdrawal of their heart surgery drug in November, Bayer AG has now indicated that they will be removing the remaining supply of Trasylol from all…